
British pharmaceutical giant GSK Plc (NYSE:GSK) on Wednesday reported upbeat third-quarter results and upgraded its full-year 2025 guidance.
GSK's third-quarter sales reached $11.53 billion (8.5 billion British pounds). That’s an 8% increase at constant currency, exceeding analyst estimates of $11.16 billion.